We are live on ! Find out more

275 hedge funds and large institutions have $4.97B invested in DexCom in 2017 Q3 according to their latest regulatory filings, with 30 funds opening new positions, 120 increasing their positions, 82 reducing their positions, and 61 closing their positions.

New
Increased
Maintained
Reduced
Closed

63% more call options, than puts

Call options by funds: $30.7M | Put options by funds: $18.8M

46% more repeat investments, than reductions

Existing positions increased: 120 | Existing positions reduced: 82

18.04% more ownership

Funds ownership: 452.39%470.43% (+18%)

11% less funds holding

Funds holding: 310275 (-35)

30% less capital invested

Capital invested by funds: $7.14B → $4.97B (-$2.17B)

51% less first-time investments, than exits

New positions opened: 30 | Existing positions closed: 61

Holders
275
Holders Change
-35
Holders Change %
-11.29%
% of All Funds
6.86%
Holding in Top 10
3
Holding in Top 10 Change
+3
Holding in Top 10 Change %
% of All Funds
0.07%
New
30
Increased
120
Reduced
82
Closed
61
Calls
$30.7M
Puts
$18.8M
Net Calls
+$11.9M
Net Calls Change
+$506M

DXCM Hedge Fund Activity: Q3 2017 in Review

275 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in DexCom (DXCM) for Q3 2017, worth a combined $4.97B — down 30% from $7.14B a quarter earlier.

Sellers outnumbered buyers: 61 funds closed out of DXCM and 30 opened new positions — a net loss of 31 holders — while 82 trimmed existing stakes and 120 added.

The largest buyer was Wellington Management Group, adding an estimated $458M. The largest seller was Ameriprise, cutting an estimated $277M.

  • 275 institutional investors held DexCom (DXCM) as of Q3 2017, down from 310 in Q2 2017.
  • Funds reported $4.97B of DexCom stock for Q3 2017, down 30% quarter-over-quarter.
  • 30 funds opened new DexCom positions in Q3 2017 and 61 closed out, a net change of -31 holders.
  • The largest DexCom buyer in Q3 2017 was Wellington Management Group, an estimated $458M added.
  • The largest DexCom seller in Q3 2017 was Ameriprise, an estimated $277M sold.

Based on aggregated 13F filings for Q3 2017.